Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022


Treatment with Bulevirtide, with or without PEG-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program

	AASLD 2022 Nov 4-8